Default Category
-
GSK’s Andrew Witty: Addressing Neglected Tropical Diseases and Global Health Issues — Open Labs, Open Minds (B)
Michael J. Rouse; Chander SehgalCase IVEY-9B10M110-EStrategyThis case is a supplement to GSK’s Andrew Witty (A).Starting at €5.74
-
GSK’s Andrew Witty: Addressing Neglected Tropical Diseases and Global Health Issues — The Pharmaceutical Patent Pool (A)
Michael J. Rouse; Chander SehgalCase IVEY-9B10M109-EStrategyIn February 2009, Andrew Witty, CEO of GlaxoSmithKline (GSK), reflected on his vision for big pharma as a catalyst for change which focussed on two key issues: 1) promoting innovation for the products that treat or prevent neglected tropical diseases and 2) improving access to medicines in the world’s poorest countries. He had announced the creation of the Pharmaceutical Patent Pool and wondered if it was the right strategy to deliver results on ...Starting at €8.20
-
TATE: Reinventing Operations to Become a Different Type of Company
Munoz-Seca, Beatriz; Riverola, JosepCase P-1093-EService and Operations ManagementThis case describes the current structure of operations of Tate. The challenge is to bring Tate to a new 21st century model of operations. Julian Bird its COO reviews the changes he has implemented since his arrival in 2007 and the innovation Tate faces.Starting at €8.20
-
TATE: Reinventar las operaciones para un tipo de empresa diferente
Munoz-Seca, Beatriz; Riverola, JosepCase P-1093Service and Operations ManagementEste caso describe la actual estructura de operaciones de Tate. El reto es establecer en Tate un modelo de operaciones del siglo XXI. Su director de operaciones, Julian Bird, revisa los cambios que ha implementado desde su llegada en 2007 y la innovación que afronta Tate.Starting at €8.20